

RAGHURAM SELVARAJU JOINS RODMAN & RENSHAW AS SENIOR BIOTECHNOLOGY ANALYST

NEW YORK, August 3, 2015 – Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC (“Rodman”) announced today that Raghuram Selvaraju, Ph.D. has joined the firm as a Managing Director in Equity Research. Dr. Selvaraju will be a Senior Analyst covering companies in the Biotechnology sector under the Rodman & Renshaw brand. Rodman also announced that Yi Chen, Ph.D. will join Dr. Selvaraju in leading Rodman’s biotechnology effort in small-cap companies.

Dr. Selvaraju joins Rodman from MLV & Co., where he was a Senior Biotechnology Analyst. Prior to that, he was a Senior Analyst at Aegis Capital Corp. and also held positions in biotechnology research at Morgan Joseph TriArtisan LLC, Noble International, Hapoalim Securities and Rodman & Renshaw, LLC. Prior to becoming a research analyst, Dr. Selvaraju spent five years in the biotechnology industry working as a drug development researcher for Serono S.A.

“We welcome Ram back to Rodman and are excited that he has decided to join the biotechnology team”, commented Mark Viklund, Chief Executive Officer of H.C. Wainwright & Co., LLC. “His expertise in uncovering investment opportunities in the microcap and smallcap biotechnology space will prove to be valuable to Rodman as we leverage our research coverage”.

About Rodman & Renshaw

Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC (“Rodman”) is an investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private growth companies across multiple sectors and regions. The Rodman team has been the leader in the PIPE (private investment in public equity) and RD (registered direct offering) transaction markets. Rodman recently began publishing a subset of its equity research under the Rodman & Renshaw brand to leverage its historical name recognition in several emerging growth sectors.